RICHARD LINSK: Open Payments
NPI 1356355580 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,248 in 61 payments from 13 companies in 2025. Trend: 2023 $184 · 2024 $238 · 2025 $1,248
Food & beverage: $1,248
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $261 |
| E.R. Squibb & Sons, L.L.C. | 10 | $208 |
| Vanda Pharmaceuticals Inc. | 9 | $204 |
| Janssen Pharmaceuticals, Inc | 5 | $114 |
| Neurocrine BioSciences, Inc. | 4 | $100 |
| Supernus Pharmaceuticals, Inc. | 4 | $81 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Alkermes, Inc. | 2 | $45 |
| Tris Pharma Inc | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
Products named: COBENFY, FANAPT, ABILIFY ASIMTUFII, REXULTI, INVEGA SUSTENNA, INGREZZA, Qelbree, Auvelity.
Industry payments across MI — which companies pay providers there.
